Terns’ GLP-1 pill leads to weight loss in early study

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Lots of bispecific talk on this delightful September day, as well as discussion around new concerns in Duchenne treatment as more options become available.

The need-to-know this morning

• Eli Lilly named Lucas Montarce as its new chief financial officer. Montarce has been a Lilly executive since 2001, most recently serving as president of Lilly’s Spain, Greece, and Portugal hub.
• Immunovant and Roivant Sciences reported results from a mid-stage study of their experimental drug called batoclimab in Graves disease.

With bispecifics, a biotech maverick strikes again

Summit Therapeutics, led by CEO Robert Duggan, presented groundbreaking data this weekend showing that its experimental drug, ivonescimab, dramatically outperformed the formerly unbeatable Keytruda in treating non-small cell lung cancer: Progression-free survival for the bispecific antibody drug was 11.1 months, compared to 5.8 months with Keytruda. The results could ultimately reshape the market for lung cancer drugs.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In